(Q45401234)

English

Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 December 2017

Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus (English)

1 reference

Europe PubMed Central

14 December 2017

vector-borne disease

0 references

0 references

oncolytic virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Kohno SI

1

1 reference

Europe PubMed Central

14 December 2017

Luo C

2

1 reference

Europe PubMed Central

14 December 2017

Nawa A

3

1 reference

Europe PubMed Central

14 December 2017

Fujimoto Y

4

1 reference

Europe PubMed Central

14 December 2017

Watanabe D

5

1 reference

Europe PubMed Central

14 December 2017

Goshima F

6

1 reference

Europe PubMed Central

14 December 2017

Tsurumi T

7

1 reference

Europe PubMed Central

14 December 2017

Nishiyama Y

8

1 reference

Europe PubMed Central

14 December 2017

publication date

10 August 2007

1 reference

Europe PubMed Central

14 December 2017

Cancer Gene Therapy

1 reference

Europe PubMed Central

14 December 2017

14

1 reference

Europe PubMed Central

14 December 2017

918-926

1 reference

Europe PubMed Central

14 December 2017

11

1 reference

Europe PubMed Central

14 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.cgt.7701070

0 references

Oncolytic herpes simplex virus vectors for cancer virotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

21 January 2018

Herpes simplex virus gene products: the accessories reflect her lifestyle well

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

21 January 2018

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

21 January 2018

Intralesional injection of herpes simplex virus 1716 in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

21 January 2018

HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

21 January 2018

Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

21 January 2018

Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

21 January 2018

Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

21 January 2018

Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

21 January 2018

Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

21 January 2018

Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

21 January 2018

Augmentation of antitumor immune responses by multiple intratumoral inoculations of replication-conditional HSV and interleukin-12.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

21 January 2018

Tumor regression induced by intratumor therapy with a disabled infectious single cycle (DISC) herpes simplex virus (HSV) vector, DISC/HSV/murine granulocyte-macrophage colony-stimulating factor, correlates with antigen-specific adaptive immunity.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

21 January 2018

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

21 January 2018

Helper virus-free herpes simplex virus type 1 amplicon vectors for granulocyte-macrophage colony-stimulating factor-enhanced vaccination therapy for experimental glioma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

21 January 2018

Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

21 January 2018

A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

21 January 2018

The herpes simplex virus amplicon: A new eucaryotic defective-virus cloning-amplifying vector

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

21 January 2018

Paracrine cytokine adjuvants in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

21 January 2018

Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

21 January 2018

Herpes simplex virus type 1 mutant HF10 oncolytic viral therapy for bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

21 January 2018

Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

21 January 2018

Treatment of solid sarcomas in immunocompetent mice with novel, oncolytic herpes simplex viruses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

21 January 2018

Intratumoral injection of herpes simplex virus HF10 in recurrent breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

21 January 2018

Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

21 January 2018

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

21 January 2018

Growth and cytopathogenicity of herpes simplex virus in a macrophage cell line, RAW264: A good indicator of intraperitoneal pathogenicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

21 January 2018

A sequence in HpaI-P fragment of herpes simplex virus-1 DNA determines intraperitoneal virulence in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

21 January 2018

Herpes simplex virus type 1 (HSV-1) UL56 gene is involved in viral intraperitoneal pathogenicity to immunocompetent mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

21 January 2018

Identification and characterization of the UL56 gene product of herpes simplex virus type 2.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

21 January 2018

Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

21 January 2018

Oncolytic viruses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

7 January 2021

based on heuristic

inferred from DOI database lookup

The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

7 January 2021

based on heuristic

inferred from DOI database lookup

Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

7 January 2021

based on heuristic

inferred from DOI database lookup

Regulation of CTL responses to MHC-restricted class I peptide of the gp70 tumour antigen by splenic parenchymal CD4+ T cells in mice failing immunotherapy with DISC-mGM-CSF

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination vascular delivery of herpes simplex oncolytic viruses and amplicon mediated cytokine gene transfer is effective therapy for experimental liver cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

7 January 2021

based on heuristic

inferred from DOI database lookup

The dendritic cell system and its role in immunogenicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

7 January 2021

based on heuristic

inferred from DOI database lookup

An enhanced packaging system for helper-dependent herpes simplex virus vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701070

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.CGT.7701070

1 reference

Europe PubMed Central

14 December 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

14 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45401234&oldid=2076616465"